SEARCH:   Advanced

Blood, 1 January 2009, Vol. 113, No. 1, pp. 18-27. Prepublished online as a Blood First Edition Paper on September 22, 2008; DOI 10.1182/blood-2008-06-165654. This Article Full Text (PDF) Supplemental Figure All Versions of this Article: blood-2008-06-165654v1 113/1/18    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Di Nicola, M. Articles by Gianni, A. M Search for Related Content PubMed PubMed Citation Articles by Di Nicola, M. Articles by Gianni, A. M Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted June 27, 2008 Accepted August 26, 2008 Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunological responses in indolent B cell lymphoma patients with relapsed and measurable disease: a pilot study Massimo Di Nicola*, Roberta Zappasodi, Carmelo Carlostella, Roberta Mortarini, Serenella M Pupa, Michele Magni, Liliana Devizzi, Paola Matteucci, Paola Baldassari, Fernando Ravagnani, Antonello Cabras, Andrea Anichini, and Alessandro M Gianni "C. Gandini" Bone Marrow Transplantation Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy Human Tumor Immunobiology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy Pathology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy * Corresponding author; email: massimo.dinicola{at}istitutotumori.mi.it. Eighteen relapsed patients with measurable indolent non-Hodgkin lymphoma (NHL) were vaccinated with dendritic cells (DCs) loaded with killed autologous tumor cells. Six patients had objective clinical responses including three continuous complete remissions (CR) and three partial responses (PR), with a median follow-up of 50.5 months. Eight patients had stable disease, while four had progressive disease. Clinical responses were significantly associated with a reduction in CD4+CD25+FOXP3+ regulatory T cells, an increase in CD3-CD56dimCD16+ NK cells and maturation of lymphocytes to the effector memory stage either in post-vaccine peripheral blood or tumor specimen samples. In partial responding patients, vaccination significantly boosted the IFN- producing T cell response to autologous tumor challenge. In one HLA-A*0201+ patient that achieved CR, IL-4 release by circulating T cells in response to tumor-specific IgH-encoded peptides was also documented. Immunohistochemical analysis of tumor biopsies using biotin-conjugated autologous serum samples revealed a tumor-restricted humoral response only in the post-vaccine serum from responding patients, whereas no autologous tumor-specific reactivity was detected in pre- or post-vaccine sera from non-responder patients. Collectively these results demonstrate that vaccination with tumor-loaded DCs may induce both T and B cell responses and produces clinical benefits in indolent NHL patients with measurable disease. This study is registered with the Instituto Superiore di Sanita: http://www.iss.it with protocol number 7578-PRE 21-801 CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Cancer vaccines: up, down, ... up again? Sattva S. Neelapu and Larry W. Kwak Blood 2009 113: 1-2. [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020